

# Jochen Seufert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/313219/publications.pdf>

Version: 2024-02-01

68

papers

5,835

citations

304743

22

h-index

110387

64

g-index

70

all docs

70

docs citations

70

times ranked

7217

citing authors

#	ARTICLE	IF	CITATIONS
1	Switching the basal insulin to insulin glargine 300â€‰%U/â€‰ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety. Diabetes, Obesity and Metabolism, 2022, 24, 72-81.	4.4	3
2	Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (â€‰DPVâ€‰) database. Diabetes, Obesity and Metabolism, 2022, 24, 727-732.	4.4	5
3	â€‰Real-worldâ€‰ data of 12-month adjunct sodium-glucose co-transporterâ€‰2 inhibitor treatment in type 1 diabetes from the â€‰German/Austrian DPVâ€‰ registry: Improved â€‰HbA1câ€‰ without diabetic ketoacidosis. Diabetes, Obesity and Metabolism, 2022, 24, 742-746.	4.4	14
4	Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Follow-up Registry. Diabetes, Obesity and Metabolism, 2022, 24, 2253-2262.	4.4	1
5	Cardiovascular protection by SGLT2 inhibitors â€‰“ Do anti-inflammatory mechanisms play a role?. Molecular Metabolism, 2022, 64, 101549.	6.5	23
6	Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study. Diabetes Therapy, 2021, 12, 733-747.	2.5	1
7	Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study. Diabetes Therapy, 2021, 12, 749-764.	2.5	1
8	The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes/Metabolism Research and Reviews, 2021, 37, e3430.	4.0	44
9	Stereotactic cysternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial. Trials, 2021, 22, 285.	1.6	2
10	Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations â€‰“ a registry-based analysis. BMC Nephrology, 2021, 22, 184.	1.8	13
11	Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The â€‰SAGEâ€‰ study. Diabetes, Obesity and Metabolism, 2021, 23, 1892-1901.	4.4	5
12	Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes, Obesity and Metabolism, 2021, 23, 2595-2599.	4.4	27
13	Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid, 2021, 31, 1076-1085.	4.5	96
14	Durch FÃ¶rderung des diabetologischen Nachwuchses in der DDG exzellente Forschung und Patientenversorgung zukunftsicher aufstellen â€‰“ Hellmut-Otto-Medaille 2021 - Kurzblick der PreistrÃ¶ger Annette SchÃ¶rmann und Jochen Seufert. Diabetologie Und Stoffwechsel, 2021, 16, 467-468.	0.0	0
15	Clinical Impact of the TCF7L2 Gene rs7903146 Type 2 Diabetes Mellitus Risk Polymorphism in Women with Gestational Diabetes Mellitus: Impaired Glycemic Control and Increased Need of Insulin Therapy. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 663-666.	1.2	9
16	Titration of insulin glargine 100â€‰U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. Acta Diabetologica, 2020, 57, 89-99.	2.5	7
17	Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries. Acta Diabetologica, 2020, 57, 229-236.	2.5	4
18	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, Obesity and Metabolism, 2020, 22, 346-354.	4.4	6

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of insulin glargine 300â€‰U/mL in insulinâ€‰naïve patients with type 2 diabetes after failure of oral therapy in a realâ€‰world setting. Diabetes, Obesity and Metabolism, 2020, 22, 759-766.	4.4	10
20	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	1.9	12
21	Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome. Obesity Surgery, 2020, 30, 1200-1210.	2.1	10
22	Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882095829.	3.2	7
23	The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany. BMJ Open Diabetes Research and Care, 2020, 8, e001486.	2.8	2
24	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1â€‰7 randomised controlled trials. Lancet Diabetes and Endocrinology, the, 2020, 8, 880-893.	11.4	86
25	NUPR1 preserves insulin secretion of pancreatic Î²-cells during inflammatory stress by multiple low-dose streptozotocin and high-fat diet. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E338-E344.	3.5	13
26	Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy, 2020, 11, 1645-1666.	2.5	27
27	Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. Clinical Nuclear Medicine, 2020, 45, 519-524.	1.3	9
28	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4078-4086.	3.6	25
29	Event Rates and Risk Factors for the Development of Diabetic Ketoacidosis in Adult Patients With Type 1 Diabetes: Analysis From the DPV Registry Based on 46,966 Patients. Diabetes Care, 2019, 42, e34-e36.	8.6	22
30	Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries. Advances in Therapy, 2019, 36, 1628-1641.	2.9	5
31	Comparative Dose Accuracy of Durable and Patch Insulin Pumps Under Laboratory Conditions. Diabetes Technology and Therapeutics, 2019, 21, 371-378.	4.4	13
32	Predictors of treatment response in type 2 diabetes patients initiating basalâ€‰supported oral therapy with insulin glargine 100 U/mL: A subâ€‰analysis of the Titration and OPTimisation (TOP) registry. Diabetes, Obesity and Metabolism, 2019, 21, 2169-2173.	4.4	3
33	Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovascular Diabetology, 2019, 18, 33.	6.8	42
34	Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen. BMJ Open Diabetes Research and Care, 2019, 7, e000679.	2.8	8
35	Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Diabetes, Obesity and Metabolism, 2019, 21, 439-443.	4.4	9
36	Stem cells in the treatment of diabetes mellitus â€” Focus on mesenchymal stem cells. Metabolism: Clinical and Experimental, 2019, 90, 1-15.	3.4	88

#	ARTICLE	IF	CITATIONS
37	Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents.. , 2019, 4, 29-49.		11
38	Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner. Surgery for Obesity and Related Diseases, 2018, 14, 769-779.	1.2	14
39	Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes, Obesity and Metabolism, 2018, 20, 1868-1877.	4.4	20
40	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	3.7	26
41	Mesenchymal stem cell (MSC)-mediated survival of insulin producing pancreatic Î²-cells during cellular stress involves signalling via Akt and ERK1/2. Molecular and Cellular Endocrinology, 2018, 473, 235-244.	3.2	11
42	Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL). Obesity Surgery, 2018, 28, 2187-2196.	2.1	8
43	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 620-628.	4.4	121
44	17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3601-3610.	3.6	39
45	Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterology, 2018, 18, 118.	2.0	5
46	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2598-2607.	4.4	48
47	Ischemic Duodenal Ulceration after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report. Case Reports in Gastroenterology, 2018, 12, 352-359.	0.6	3
48	Comparative Characteristics of Patients with Type 2 Diabetes Mellitus Treated by Bariatric Surgery Versus Medical Treatment: a Multicentre Analysis of 277,862 Patients from the German/Austrian DPV Database. Obesity Surgery, 2018, 28, 3366-3373.	2.1	3
49	Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
50	Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries. Diabetes/Metabolism Research and Reviews, 2018, 34, e3049.	4.0	8
51	Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study. Nephrology Dialysis Transplantation, 2017, 32, gfw301.	0.7	33
52	Physiology and role of irisin in glucose homeostasis. Nature Reviews Endocrinology, 2017, 13, 324-337.	9.6	403
53	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	4.4	100
54	Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries. Diabetes Care, 2017, 40, e139-e140.	8.6	44

#	ARTICLE	IF	CITATIONS
55	Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, 51-57.	3.6	3
56	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German <scp>DIVE</scp> and <scp>DPV</scp> registries. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 61-69.	4.4	9
57	Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 31-38.	2.8	38
58	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	27.0	3,898
59	Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry. <i>BMC Endocrine Disorders</i> , 2015, 15, 54.	2.2	19
60	Value of MRI and MRS fat measurements to complement conventional screening methods for childhood obesity. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1214-1222.	3.4	9
61	Effectiveness and tolerability of treatment intensification to basal&ndash;bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. <i>Vascular Health and Risk Management</i> , 2015, 11, 569.	2.3	3
62	SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 543.	2.4	51
63	Minimally invasive treatment of a duodenal perforation associated with the EndoBarrier duodenal –jejunal bypass liner. <i>Endoscopy</i> , 2014, 46, E171-E172.	1.8	9
64	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 115-122.	11.4	153
65	Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. <i>Vascular Health and Risk Management</i> , 2013, 9, 711.	2.3	9
66	The backbone of oral glucose –lowering therapy: time for a paradigm shift?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 651-667.	1.9	0
67	2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 453-460.	2.8	29
68	A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. <i>Current Medical Research and Opinion</i> , 2006, 22, S39-S48.	1.9	14